Aprobation of platelet aggregation inhibitor from Echis multisquamatis snake venom in vitro, in vivo and ex vivo
Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients. Our study aimed to assess the effectiveness of a platelet aggregation inhibitor derived fro...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
National Academy of Sciences of Ukraine, Palladin Institute of Biochemistry
2023-10-01
|
| Series: | Biotechnologia Acta |
| Subjects: | |
| Online Access: | https://biotechnology.kiev.ua/images/BTA/2023/5_2023/Zhelavskyi5_2023.pdf |
| Summary: | Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients. Our study aimed to assess the effectiveness of a platelet aggregation inhibitor derived from Echis multisquamatis snake venom in various settings, including in vitro, in vivo, and ex vivo.
Methods. We examined a polypeptide from Echis multisquamatis venom, purified using a recently developed chromatography protocol, across multiple models. This polypeptide was introduced into platelet-rich blood plasma and administered intravenously to rats. The effects on platelet aggregation were assessed using aggregometry, focusing on ADP-induced aggregation.
Results & Discussion. Our findings revealed that a concentration of 0.040 mg/ml significantly reduced platelet aggregation in vitro. Remarkably, this dosage also proved effective when administered intravenously in laboratory animals, reaffirming its potential as a robust antiplatelet agent. In the final phase of our study, the polypeptide demonstrated its ability to inhibit platelet aggregation in blood plasma of pregnant woman with aspirin resistance, presenting a promising avenue for innovative treatment approaches in such cases.
Conclusion. This study underscores the potential of the Echis multisquamatis venom-derived polypeptide as a promising antiplatelet agent, effective in diverse scenarios, including aspirin resistance. Further research and clinical trials are imperative to fully harness its therapeutic potential. |
|---|---|
| ISSN: | 2410-7751 2410-776X |